Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

rtisol levels in Cushing's disease, 13 (8.0%) patients experienced adverse events associated with cortisol levels below the normal range. This was managed by dose reduction without loss of efficacy(1).

About Cushing's diseaseCushing's disease is a rare but serious disease that affects approximately 10 to 15 patients per million per year. It most commonly affects adults who are as young as 20 to 50 years and affects women three times more often than men. Cushing's disease presents with weight gain, central obesity, moon face, severe fatigue and weakness, striae (purple stretch marks), depression and anxiety(2),(5). To date, no known causes or risk factors have been identified for the development of the benign tumors in the pituitary gland that cause Cushing's disease.

Complications of Cushing's disease can include osteoporosis and subsequently fractures, insulin resistance with higher prevalence of impaired glucose tolerance and diabetes mellitus, high blood pressure, lipid disorders, infections, kidney stones and mental illnesses, including depression and psychosis(1),(3),(4). Cardiovascular complications resulting from untreated Cushing's disease, including coronary artery disease, congestive heart failure and stroke, contribute to a mortality rate up to four times higher than the healthy population(4).

The most common treatment approach for Cushing's disease is surgical removal of the tumor. Persistent disease and/or relapse can occur in up to 50% of surgery patients(2),(5). If surgery is not appropriate or effective, other treatment options include radiation to the pituitary gland, stereotactic radiosurgery or gamma knife radiation, removal of the adrenal glands and inhibition of cortisol production(2).

About SOM230 (pasireotide)SOM230 is an investigational pituitary-directed therapy that targets the cause of Cushing's disease, with the aim to control excess cortisol secretion and its debilitating complications(1),(2). SOM
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Noser Health and Netcetera ... deliver new platform   ... data transaction platform, announced today strategic partnerships with ... and bring to market its global health data transaction ... "Our business model is built on trust, neutrality, impact ...
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., ... of cancer, today announced the filing of a registration ... Exchange Commission (SEC) relating to a proposed initial public ... to be offered and the price range for the ... list its common stock under the symbol "CTMX" on ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Tobramycin Market, 2010-2019" ... a traditional antibiotic whose eye drop and ointment are ... potential infection or inflammation caused by eye infection. Currently, ... are able to produce tobramycin, among which the Top ...
Breaking Medicine Technology:healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 2healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 3healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 4CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... 3 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that the Company has licensed to Targacept, ... patents and library of preclinical compounds that target the ...
... , SHANGHAI , ... Shanghai based,life science research service company, and Bio ... research service company, announced today the completion of,a ... The company is using the,funding to scale research & ...
Cached Medicine Technology:Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 2Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 3Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 4Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 2Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 3
(Date:8/31/2015)... ... August 31, 2015 , ... Move over shave cream. ... men and barbershops are scrambling to meet it. , Reports published this year (Mintel ... and haircare. But the data also reflects that men are getting more done at ...
(Date:8/31/2015)... ... 2015 , ... A year ago this month, Seniors Guide first hit stands ... issue commemorating the successful first year. , “We started the magazine with the ... in their lives,” says Melissa Wolfert, founding Publisher for Seniors Guide Columbus. “Making the ...
(Date:8/31/2015)... ... 2015 , ... Chicago-based company The Mood Factory, with brand ... and awareness for breast and ovarian health. During September and October, The ... to Bright Pink® to encourage households, dorms, and offices around the U.S. to ...
(Date:8/31/2015)... ... ... It’s a lot like coming home. Life-long Fox Valley resident James Holbrook has been ... the job, he’s run into residents of the retirement community who he’s known since ... in such a wonderful place,” he said. GreenFields, which is sponsored by Friendship Senior ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... networking and relationship-marketing firm, announced today the nominees vying for the 2015 ... U.S. Region. Executives include top-ranking decision makers representing national to global organizations ...
Breaking Medicine News(10 mins):Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 2Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 3Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 4
... New research has found that hormone therapy used to treat ... chance of developing various heart problems. Some choices of therapy ... Researchers told Europe,s biggest cancer congress, ECCO 15 ESMO ... findings of their study, the largest and most comprehensive to ...
... , MAHWAH, N.J., Sept. 22 Radware ... application delivery solutions for business-smart networking, today announced ... and South Carolina, has leveraged Radware,s suite of application delivery solutions ... load balancing capabilities for its extensive hospital system. ...
... , , RANDOLPH, Mass., Sept. 22 ... to serving individuals with Autism Spectrum Disorders (ASD), today released its ... and adolescents with ASD ever published. , , ... information about the myriad treatments available for ASD," said Susan M. ...
... Germany, September 22 The,Gerresheimer Group expands its ... significant investments in the USA and,Europe. This week ... research,and development center for medical plastic systems in ... for pharmaceutical plastic packaging in Spain.,"Plastics are increasingly ...
... Corrie Yackulic, ... after nearly twenty years to open her own personal injury law practice. , ... Seattle, Wash. (Lexis Nexis) September 22, 2009 ... at personal injury law firm Schroeter Goldmark & Bender to launch her own personal injury ...
... ... Pelvic Organ Prolapse --provides helpful information about the common conditions of urinary incontinence and ... symptoms, as well as the symptoms of pelvic organ prolapse. Finally, treatment options are ... ...
Cached Medicine News:Health News:Prostate cancer patients on hormone therapy at increased risk for various heart diseases 2Health News:Prostate cancer patients on hormone therapy at increased risk for various heart diseases 3Health News:Prostate cancer patients on hormone therapy at increased risk for various heart diseases 4Health News:Radware Prevents Network Downtime for Carolinas HealthCare System, One of the Largest Healthcare Systems in the U.S. 2Health News:Radware Prevents Network Downtime for Carolinas HealthCare System, One of the Largest Healthcare Systems in the U.S. 3Health News:Radware Prevents Network Downtime for Carolinas HealthCare System, One of the Largest Healthcare Systems in the U.S. 4Health News:Radware Prevents Network Downtime for Carolinas HealthCare System, One of the Largest Healthcare Systems in the U.S. 5Health News:National Autism Center Releases Groundbreaking Report on Autism Treatments 2Health News:National Autism Center Releases Groundbreaking Report on Autism Treatments 3Health News:Gerresheimer Expands in the Global Pharmaceutical Plastic Business 2Health News:Gerresheimer Expands in the Global Pharmaceutical Plastic Business 3Health News:Seattle Personal Injury Attorney Corrie Yackulic Opens Law Firm, Unveils New Website 2Health News:Women's Pelvic Organ Prolapse and Incontinence Guide Informs, Outlines Treatments 2Health News:Women's Pelvic Organ Prolapse and Incontinence Guide Informs, Outlines Treatments 3
BETADINE® Surgical Scrub is a microbicidal, sudsing cleanser that promptly kills most bacteria, fungi, viruses, protozoa and yeasts. It is indicated for hand hygiene, surgical hand-scrubbing, an...
... Topical, Bactericide, Microbicide for professional ... technology in skin disinfectants combining quaternary ... a synergistic blend of emollients and ... and gram-positive organisms tested in 30 ...
... bonds with the skin ... germ-killing field. In addition ... antimicrobial effect, HIBICLENS' non-drying, ... promotes compliance with the ...
... solution, allows the user to prep one ... in less than 2-minutes. It also utilizes ... surgical scrubbing and healthcare personnel handwashing. ACTIPREP ... provide a tacky surface for drapes to ...
Medicine Products: